Cessatech AS
8GN
Company Profile
Business description
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. Its product (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. Its other products CT002 which is a Non-invasive nasal spray and CT003 which is a local anaesthetic gel are in different stages development.
Contact
Strandvejen 60
HellerupDK- 2900
DNKT: +45 93872309
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
Cheapest ASX member of our Best Idea’s list
This share is trading at the lowest price to fair value of the 14 companies on the list.
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,996.90 | 78.80 | -0.87% |
| CAC 40 | 8,240.46 | 28.96 | 0.35% |
| DAX 40 | 24,940.31 | 71.62 | 0.29% |
| Dow JONES (US) | 49,145.08 | 167.90 | 0.34% |
| FTSE 100 | 10,122.44 | 117.87 | 1.18% |
| HKSE | 26,710.45 | 363.21 | 1.38% |
| NASDAQ | 23,506.37 | 110.54 | 0.47% |
| Nikkei 225 | 52,518.08 | 685.28 | 1.32% |
| NZX 50 Index | 13,663.58 | 76.35 | 0.56% |
| S&P 500 | 6,930.33 | 28.28 | 0.41% |
| S&P/ASX 200 | 8,682.80 | 88.50 | -1.01% |
| SSE Composite Index | 4,083.67 | 60.25 | 1.50% |